<DOC>
	<DOCNO>NCT01569074</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness four dose regimen fostamatinib compare placebo , patient rheumatoid arthritis ( RA ) take methotrexate responding . The study last 12 week .</brief_summary>
	<brief_title>Evaluation Safety Effectiveness Fostamatinib Compared Placebo Patients Asia With Rheumatoid Arthritis</brief_title>
	<detailed_description>( OSKIRA-Asia-1 ) : A Multi-centre , Randomised , Double-Blind , Placebo-Controlled , Parallel Group Dose Ranging Study Asia Evaluating Efficacy Safety Fostamatinib Patients Active Rheumatoid Arthritis Inadequate Responders Methotrexate Therapy</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Male female age 18 Active rheumatoid arthritis ( RA ) diagnose age 16 6 swollen joint 6 tender/painful joint certain joint hand , wrist , arm knee At least one : positive result rheumatoid factor test , either past currently ( blood test ) ; xray show bone erosion within last 12 month ; presence certain antibody blood ( blood test ) Currently take methotrexate least 4 month ( stable dose least 6 week ) Females pregnant breast feed Certain inflammatory condition ( rheumatoid arthritis ) , connective tissue diseases chronic pain disorder . Previously take , respond , certain biological treatment rheumatoid arthritis High blood pressure control medication Low level neutrophils blood ( blood test ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>